p.114 抽出テキスト

new model of maximalized follow-up. Eur Heart J 2010;31:3084–3093. https://doi.org/ 10.1093/eurheartj/ehq308 770. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA III, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 2013;61: 1527–1535. https://doi.org/10.1016/j.jacc.2013.01.037 771. Ostman-Smith I, Sjoberg G, Rydberg A, Larsson P, Fernlund E. Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy: the importance of the ECG risk score. Open Heart 2017;4:e000658. https://doi.org/10.1136/openhrt-2017- 000658 772. Ziolkowska L, Turska-Kmiec A, Petryka J, Kawalec W. Predictors of long-term outcome in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2016;37: 448–458. https://doi.org/10.1007/s00246-015-1298-y 773. Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998;32:1943–1950. https://doi.org/10.1016/S0735-1097(98)00493-8 774. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998;79:331–336. https://doi.org/10.1136/hrt.79.4.331 775. Jensen MK, Jacobsson L, Almaas V, van Buuren F, Hansen PR, Hansen TF, et al. Influence of septal thickness on the clinical outcome after alcohol septal alation in hypertrophic cardiomyopathy. Circ Cardiovasc Interv 2016;9:e003214. https://doi.org/10.1161/ CIRCINTERVENTIONS.115.003214 776. Nakajima S, Morioka S. [Effects of plasminogen activator on epidermal cell migration]. Nihon Hifuka Gakkai Zasshi 1990;100:1199–1201. 777. Balaji S, DiLorenzo MP, Fish FA, Etheridge SP, Aziz PF, Russell MW, et al. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study. Heart Rhythm 2019;16:1462–1467. https://doi.org/10.1016/j.hrthm.2019.04.040 778. Bharucha T, Lee KJ, Daubeney PE, Nugent AW, Turner C, Sholler GF, et al. Sudden death in childhood cardiomyopathy: results from a long-term national populationbased study. J Am Coll Cardiol 2015;65:2302–2310. https://doi.org/10.1016/j.jacc. 2015.03.552 779. McMahon CJ, Nagueh SF, Pignatelli RH, Denfield SW, Dreyer WJ, Price JF, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004;109: 1756–1762. https://doi.org/10.1161/01.CIR.0000124723.16433.31 780. Ostman-Smith I, Wettrell G, Keeton B, Riesenfeld T, Holmgren D, Ergander U. Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. Cardiol Young 2005;15:632–642. https://doi.org/10.1017/S1047951105001824 781. Efthimiadis GK, Parcharidou DG, Giannakoulas G, Pagourelias ED, Charalampidis P, Savvopoulos G, et al. Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 2009;104:695–699. https://doi.org/10.1016/j.amjcard.2009.04.039 782. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212–2218. https://doi.org/10.1016/S0735-1097(00)01003-2 783. Louie EK, Maron BJ. Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: functional and morphologic features and clinical significance. J Am Coll Cardiol 1986;8:57–65. https://doi.org/10.1016/S0735-1097(86)80092-4 784. Norrish G, Ding T, Field E, Cervi E, Ziolkowska L, Olivotto I, et al. Relationship between maximal left ventricular wall thickness and sudden cardiac death in childhood onset hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2022;15:e010075. https://doi.org/10.1161/CIRCEP.121.010075 785. Williams L, Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. Europace 2007;9:817–822. https://doi.org/10.1093/ europace/eum093 786. Sediva H, Hnat T, Bonaventura J, Slesarenko J, Veselka J. Head-up tilt test in risk stratification of patients with hypertrophic cardiomyopathy. Int J Angiol 2019;28:245–248. https://doi.org/10.1055/s-0039-1688983 787. Moak JP, Leifer ES, Tripodi D, Mohiddin SA, Fananapazir L. Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events. Pediatr Cardiol 2011;32:1096–1105. https://doi.org/ 10.1007/s00246-011-9967-y 788. Romeo F, Cianfrocca C, Pelliccia F, Colloridi V, Cristofani R, Reale A. Long-term prognosis in children with hypertrophic cardiomyopathy: an analysis of 37 patients aged less than or equal to 14 years at diagnosis. Clin Cardiol 1990;13:101–107. https://doi.org/10. 1002/clc.4960130208 789. Maskatia SA, Decker JA, Spinner JA, Kim JJ, Price JF, Jefferies JL, et al. Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2012;33:141–149. https://doi.org/10.1007/s00246-011-0106-6 790. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:480–487. https://doi.org/10.1016/j.jacc.2005.04.043 791. Yan L-R, Zhao S-H, Wang H-Y, Duan F-J, Wang Z-M, Yang Y-J, et al. Clinical characteristics and prognosis of 60 patients with midventricular obstructive hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown) 2015;16:751–760. https://doi.org/10. 2459/JCM.0000000000000163 792. Minami Y, Haruki S, Hagiwara N. Phenotypic overlap in hypertrophic cardiomyopathy: apical hypertrophy, midventricular obstruction, and apical aneurysm. J Cardiol 2014;64: 463–469. https://doi.org/10.1016/j.jjcc.2014.03.003 793. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;142:e558–e631. https://doi.org/10.1161/CIR.0000000000000937 794. Kamp NJ, Chery G, Kosinski AS, Desai MY, Wazni O, Schmidler GS, et al. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Prog Cardiovasc Dis 2021;66:10–16. https://doi.org/10.1016/j.pcad.2020.11.001 795. Kramer CM, DiMarco JP, Kolm P, Ho CY, Desai MY, Kwong RY, et al. Predictors of major atrial fibrillation endpoints in the National Heart, Lung, and Blood Institute HCMR. JACC Clin Electrophysiol 2021;7:1376–1386. https://doi.org/10.1016/j.jacep. 2021.04.004 796. Raja AA, Farhad H, Valente AM, Couce JP, Jefferies JL, Bundgaard H, et al. Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy. Circulation 2018;138:782–792. https://doi.org/10. 1161/CIRCULATIONAHA.117.032966 797. Petryka-Mazurkiewicz J, Ziolkowska L, Kowalczyk-Domagala M, Mazurkiewicz L, Boruc A, Spiewak M, et al. LGE for risk stratification in primary prevention in children with HCM. JACC Cardiovasc Imaging 2020;13:2684–2686. https://doi.org/10.1016/j. jcmg.2020.06.009 798. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990; 82:1995–2002. https://doi.org/10.1161/01.CIR.82.6.1995 799. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 1991;84:686–696. https:// doi.org/10.1161/01.CIR.84.2.686 800. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987–2991. https://doi.org/10. 1161/01.CIR.96.9.2987 801. Smith ED, Tome J, McGrath R, Kumar S, Concannon M, Day SM, et al. Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death. Int J Cardiol 2019;274:226–231. https://doi.org/10.1016/j.ijcard.2018.07.110 802. Norrish G, Cantarutti N, Pissaridou E, Ridout DA, Limongelli G, Elliott PM, et al. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis. Eur J Prev Cardiol 2017;24:1220–1230. https://doi.org/10. 1177/2047487317702519 803. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108–1114. https://doi.org/ 10.1056/NEJM199204233261703 804. Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, Solomon S, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994;93:280–285. https://doi.org/10. 1172/JCI116957 805. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, et al. Sudden death due to troponin T mutations. J Am Coll Cardiol 1997;29:549–555. https://doi.org/ 10.1016/S0735-1097(96)00530-X 806. Ackerman MJ, VanDriest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol 2002;39:2042–2048. https://doi.org/10.1016/ S0735-1097(02)01900-9 807. Garcia-Giustiniani D, Arad M, Ortiz-Genga M, Barriales-Villa R, Fernandez X, Rodriguez-Garcia I, et al. Phenotype and prognostic correlations of the converter region mutations affecting the beta myosin heavy chain. Heart 2015;101:1047–1053. https://doi.org/10.1136/heartjnl-2014-307205 808. Van Driest SL, Maron BJ, Ackerman MJ. From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy. Heart 2004;90:7–8. https://doi.org/10.1136/heart.90. 1.7 809. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 1994;89:22–32. https://doi.org/ 10.1161/01.CIR.89.1.22 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026